

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.

康聖環球基因技術有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9960)

GRANT OF SHARE OPTIONS

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”) pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that on June 30, 2026, the Company granted share options (the “**Share Options**”) to an employee of the Company (the “**Grantee**”) to subscribe for a total of 50,000 ordinary shares of the Company (the “**Shares**”), subject to and upon the terms and conditions of the post-IPO share option scheme adopted by the Company on June 22, 2021 (the “**Post-IPO Option Scheme**”). Details of the Share Options granted are set out as follows:

Date of grant:	June 30, 2026 (the “ Date of Grant ”)
Description of the Grantee:	One employee of the Company, who is not (i) a Director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined in the Listing Rules); (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; (iii) a related entity participant or service provider with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the total issued Shares (excluding treasury shares); or (iv) a senior manager of the Company, as of the date of this announcement.
Number of Share Options granted:	50,000 Share Options (each Share Option shall entitle the Grantee to subscribe for one Share)

Exercise price of the Share Options granted:	HK\$0.97 per Share, representing the highest of: (i) HK\$0.93, being the closing price of the Shares as stated in the daily quotations sheet by the Stock Exchange on the Date of Grant; and (ii) HK\$0.97, being the average of the closing prices of the Shares as stated in the daily quotations sheet by the Stock Exchange for the five business days immediately preceding the Date of Grant, subject to adjustments under the terms of the Post-IPO Option Scheme in accordance with Rule 17.03(13) of the Listing Rules.
Validity and exercise period of the Share Options:	The Share Options are valid and exercisable for a period of 10 years from the Date of Grant.
Option period of the Share Options (subject to acceptance):	The Share Options are exercisable for the period commencing from the first anniversary of the Date of Grant and ending on the day immediately preceding the tenth anniversary of the Date of Grant or the day on which the Share Options are lapsed or canceled in accordance with the terms of the Post-IPO Option Scheme (whichever is earlier).
Performance targets attached to the Share Options:	The Share Options shall not be subject to any performance target.
Clawback mechanism:	The Share Options shall not be subject to any clawback mechanism.
Financial assistance:	The Group has not provided any financial assistance to the Grantee to facilitate the purchase of Shares under the Post-IPO Option Scheme.

Subsequent to the grant of the Share Options, the number of Shares available for future grant pursuant to the Post-IPO Option Scheme is 67,871,412 Shares.

By order of the Board
Kindstar Globalgene Technology, Inc.
 康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, June 30, 2026

As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei, Ms. HUANG Lu and Dr. David Guowei WANG as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping, Mr. GU Huaming and Dr. Gang WANG as independent non-executive Directors.